#USA #3D Printing #Bradenton #Continuity Biosciences #PinPrint

Continuity Biosciences Expands into Aesthetic Drug Delivery

In a significant move to broaden its reach in the drug delivery landscape, Continuity Biosciences, LLC has recently announced a strategic investment in PinPrint, Inc. This innovative company is recognized for its cutting-edge, high-resolution 3D-printed microneedle technology. The synergy between the two organizations aims to revamp the approach towards not just therapeutic delivery, but now also in aesthetic and cosmetic applications, a shift that promises to enhance the long-term strategic value of Continuity’s portfolio.

PinPrint's Transformation in Drug Delivery
At the core of PinPrint's offering is a promising microneedle patch designed to deliver vaccines and other active compounds intradermally. Traditional needle injections often cause discomfort and anxiety among patients, but PinPrint aims to change that narrative. According to Dr. Joseph DeSimone, a leading chemist and the mind behind this revolutionary technology, the integration of high-resolution 3D printing could redefine patient experiences across both therapeutic and cosmetic categories. He notes, "By integrating high-resolution 3D printing with advanced drug delivery, we’re redefining the patient experience across therapeutic and cosmetic categories—offering a new standard for precision, personalization, and comfort."

The advanced technology allows the creation of ultra-precise microchannels essential for biomedical applications like microneedle patches and microfluidic devices, eliminating the over-curing of resin that has been a barrier in the past. This alignment of creativity and technology indicates a significant leap forward in patient-first drug delivery approaches.

Future Directions and Innovations
The strategic investment also extends Continuity's mission of advancing targeted drug delivery technologies. Currently, the company is enriching its portfolio through collaborative initiatives such as the development of implanted nanofluidic platforms in partnership with the Grattoni Lab at Houston Methodist Hospital. These cutting-edge platforms are designed for extended, zero-order release of medications, pushing the limits of what drug delivery systems can achieve. Ramakrishna Venugopalan, PhD, Co-Founder and CEO of Continuity Biosciences, expresses enthusiasm for the new direction. He states, "This investment allows us to expand from implanted nanofluidic systems to a non-implanted microfluidic platform, opening doors for a more effective delivery system for dermatologic, aesthetic, and cosmetic agents directly into the dermis."

As part of the transaction, Dr. Venugopalan will now join the Board of Directors at PinPrint. The leadership team at PinPrint welcomes this development with optimism, Anticipating that Dr. Venugopalan’s domain expertise and strategic direction will play a crucial role in elevating their initiatives.

About the Companies

Continuity Biosciences specializes in developing innovative drug delivery mechanisms focused on treating chronic and complex diseases. Based in Bradenton, Florida, with operational ties in Houston, Texas, the company is committed to refining the precision and efficacy of therapeutic solutions. For more information about their ongoing projects and innovative technologies, visit continuitybiosciences.com.

PinPrint, Inc. is dedicated to transforming drug and vaccine administration through their state-of-the-art 3D-printed microneedle platforms. Their focus on precision and patient comfort aims to revolutionize both therapeutic and aesthetic applications, ultimately reshaping the healthcare landscape.

In conclusion, this collaboration between Continuity Biosciences and PinPrint Inc. sets an exciting precedent for the future of drug delivery, emphasizing comfort, precision, and the rethinking of traditional methodologies that have long been standard practice.